A series of cyclopropane-based conformationally restricted γ-aminobutyric acid (GABA) analogs with stereochemical diversity, i.e., the transand cis-2,3-methano analogs Ia and Ib and their enantiomers ent-Ia and ent-Ib, and also the transand cis-3,4-methano analogs IIa and IIb and their enantiomers ent-IIa and ent-Iib, were synthesized from the chiral cyclopropane units Type-a and Type-b that we developed. These analogs were systematically evaluated with four GABA transporter (GAT) subtypes.
Introduction
Blockade of neurotransmitter uptake by inhibition of their transporters increases the neurotransmitter level in the synaptic cleft to enhance synaptic transmission, which can be an effective strategy for drug therapy of central nervous system (CNS) diseases. Serotonin-selective reuptake inhibitors (SSRI) have been successfully developed as antidepressants, and SSRI are now the most widely used of all antidepressants, due to their effectiveness as well as their clinical safety and tolerability. 1 γ-Aminobutyric acid (GABA, 1 in Figure 1 ) is a major inhibitory neurotransmitter in the CNS, whose activity in the synaptic cleft is terminated upon its reuptake by the transporters of GABAergic neuronal cells and astroglial cells. 2 Inhibition of GABA reuptake by its transporters is thought to be an effective drug development strategy targeting the GABAergic neuronal system. 3 Four GABA transporter (GAT) subtypes, i.e., GAT1, GAT2, GAT3, and BGT1 (betaine-GABA transporter1) are expressed in brain. 2, 3 Among these subtypes, GAT1 and GAT3 may be druggable targets, since the two subtypes are more highly expressed than the other two subtypes in brain, and their expression in presynaptic neurons and astrocytes may regulate GABA levels in the synaptic cleft of the GABAergic neuronal system. 2c,4 Accordingly, GABAergic synaptic transmission is likely to be enhanced effectively by inhibiting the GAT1 and/or GAT3 subtypes. In fact, tiagabine (6, Figure 1 ), a GAT1-selective inhibitor, is clinically effective for the treatment of epilepsy. 5 Figure 1 . GABA (1), hydrophilic small molecular leads 2-5 for developing GAT inhibitors, and resulting potent GAT inhibitors 6-9.
Extensive studies have been performed to develop selective inhibitors of GABA transporter subtypes, in which hydrophilic small molecular compounds, such as (R)-nipecotic acid [(R)-2], (S)-nipecotic acid [(S)-2], guvacine (3) and their bioisosteres 4 and 5, have been mainly utilized as leads. 2, [5] [6] [7] These studies have produced potent GAT1-selective inhibitors, including the clinical drug tiagabine (6). In these GAT inhibitors reported, (S)-SNAP-5114 (7) , a hydrophobic analog of (S)-2, is the most potent GAT3 inhibitor 
Results and Discussion
Cyclopropane-Based Conformationally Restricted GABA Analogs. GABA is conformationally very flexible due to its central "-C(sp 3 )-C(sp 3 )-C(sp 3 )-" backbone, and accordingly, it can assume a variety of conformations, which may make it possible to bind to different proteins, i.e., transporter subtypes as well as receptor subtypes, maybe in its different conformations. Therefore, the conformation binding to one transporter subtype, i.e., the bioactive conformation, might be different from that binding to other transporter subtypes. Proper conformational restriction of GABA may thus allow us to identify transporter inhibitors with subtype-selectivity.
In conformationally restricted GABA analogs selectively bound to the target protein, the ionic functional carboxy and amino groups, which are likely to be essential for binding, would assume a special 
Conformationally Restricted
Analogs of GABA arrangement superimposing the bioactive conformation, in which the two functional groups effectively interact with certain amino acid residues in the binding pocket of the protein. The bioactive conformations of GABA for the binding to its each transporter subtype, however, is unknown. Thus, we planned to use a stereochemical diversity-oriented strategy to design conformationally restricted analogs, where the versatile chiral cyclopropane units ( Figure 2 ) can be effectively used as described below.
For the design of conformationally restricted analogs, it is essential that the analogs are as similar as possible to the parent compound in size, shape, and molecular weight (MW). Because of its characteristic rigid and small structural features, a cyclopropane ring is effective for rigidly restricting the conformation of a molecule while leaving intact the chemical and physical properties of the lead compounds. 9,10
We designed a series of cyclopropane-based conformationally restricted GABA analogs, which are the transand cis-2,3-methano analogs Ia and Ib and their enantiomers ent-Ia and ent-Ib, and also the transand cis-3,4-methano analogs IIa and IIb and their enantiomers ent-IIa and ent-IIb. 11 In these conformationally restricted analogs having a 2,3-or a 3,4-methanobutyl backbone, the carboxyl and amino moieties are located in a variety of spatial arrangements depending on their regio-and stereochemistries. Accordingly, the spatial location of the carboxy and amino functions of one of the series might produce a bioactive conformation of GABA for binding to a target protein, and therefore, we expected that a new lead useful for the development of the selective inhibitors might be identified.
As a general observation, during the process of lead optimization, MW of the compounds usually increases, where hydrophobic moieties are often added onto the lead structure to result in an increasing logP of compounds, interfering with the desired pharmacokinetic properties of the compounds. 12, 13 Accordingly, hydrophilic low-MW leads are generally favorable, even if the affinity for the target is not very strong. From this viewpoint, the cyclopropane-based conformationally restricted GABA analogs just have a hydrophilic low-MW structural feature suitable for an efficient lead.
Synthesis.
Although much effort has been devoted to developing practical methods for preparing chiral cyclopropanes, stereoselective synthesis of cyclopropane derivatives with the desired stereochemistry is often troublesome. 14 In fact, although some of the cyclopropane-based conformationally restricted analogs of GABA have been synthesized, these are racemic or obtained by optical resolution. 11 To solve this problem, we previously developed the chiral cyclopropane units Type-a, comprising four stereoisomeric cyclopropane derivatives 10 and 11, and their enantiomers ent-10 and ent-11 bearing two adjacent carbon substituents in a trans or a cis orientation, as shown in Figure 2 . 9a,c These units are generally useful for synthesizing a series of stereoisomeric cyclopropane compounds having an asymmetric transor cis-cyclopropane structure.
Scheme 1

Scheme 2
In this study, we developed alternative cyclopropane units Type-b with a Weinreb amide moiety The trans-3,4-methano analog IIa was prepared from unit 10 as shown in Scheme 4. A Wittig reaction of unit 10 with MeOCH 2 Ph 3 Cl/NaN(TMS) 2 , followed by acidic treatment, gave the corresponding one carbon-elongated aldehyde, which was reduced with NaBH 4 in MeOH to produce the primary alcohol 22. The cis-3,4-methano analog IIb was prepared from unit 11, according to a procedure similar to that used to synthesize IIa (Scheme 5). The enantiomers ent-IIa and ent-IIb were synthesized from the units ent-10 and ent-11, respectively.
Benzylation
Thus, the target compounds were systematically and effectively synthesized using the Type-a and Type-b cyclopropane units.
Effects on GABA Transporters. The inhibitory effects of 100 μM GABA analogs on GABA uptake in GAT1/CHO, GAT2/CHO, GAT3/CHO, and BGT1/CHO cells were examined ( Table 1 ). The analog IIa showed high efficacy for GAT3 and BGT1 and moderate and low efficacy for GAT2 and GAT1, respectively. On the other hand, the other analogs showed only low to moderate efficacies for all of the GAT subtypes. Thus, potency of analog IIa at the four cloned GAT subtypes were compared to some commercial available GAT inhibitors with IC 50 values ( Table 2) . Analog IIa showed high affinity for BGT1, similar to that of NNC 05-2090, a potent BGT1-selective inhibitor. Analog IIa also showed higher affinities at GAT2 and GAT3 compared with those of β-alanine, a GAT2/3-selective inhibitor, although its affinity at GAT2 and GAT3 was lower than that of SNAP-5114, the most potent GAT2/3 inhibitor known so far. (Table 3) . 15 At a 1 μM concentration, none of the analogs synthesized in this study significantly competed with [ 3 H]GABA for GABA B receptors at 1 μM. At a 10 μM concentration, Ia, ent-Ia, and ent-IIa had weak inhibitory effects on [ 3 H]GABA binding, although analog IIa, identified as a potent GAT inhibitor, was inactive. In the same experiment, (±)-baclofen (10 nM -10 μM) competed with [ 3 H] GABA for brain GABA B receptors in a concentration-dependent manner, and the IC 50 value (mean±S.E., n=3) to displace 50% of control specific binding was 0.36±0.16 μM.
We then evaluated the inhibitory effects of 100 μM GABA analogs on [ 3 H]muscimol binding to mouse brain membrane fraction ( Figure 3A) . Analogs Ia and IIa completely displaced 5 nM [ 3 H]muscimol binding to the membrane fraction. Scatchard analysis showed that the K d value of muscimol was 15.2 nM.
Competition binding assay revealed that analog IIa showed rather high affinity (Ki values = 0.34 μM (0.25-0.46 μM)) for GABA A receptors (Figure 3B) . Table 3 . Inhibitory effects (%) of GABA analogs on GABA binding to rat brain GABAB receptors. Figure 4A ). One-way factorial analysis of variance (ANOVA) revealed that the latency of PTZ-induced clonic convulsions was significantly prolonged by the pretreatment with analog IIa (F 4,47 = 3.82, p < 0.01) and tiagabine (F 3,52 = 3.77, p < 0.05). On the other hand, one-way factorial ANOVA revealed that the duration of the tremor was significantly increased by pretreatment with tiagabine (F 3,52 = 4.48, p < 0.01), but not significantly changed by pretreatment with analog IIa (F 4,47 = 1.96, p = 0.12; Figure 4B ). Furthermore, both analog IIa and tiagabine dose-dependently inhibited PTZ-induced tonic convulsions (ED 50 = 189 ± 104 and 43.7 ± 17.3 nmol, respectively). Tonic convulsions were significantly inhibited by the pretreatment with 1000 nmol of analog IIa (the number of mice showed tonic convulsions = 0/4) and 100 nmol of tiagabine (4/15) compared with the saline-pretreated group (10/17; p < 0.05, chi-square test).
Discussion.
Although the synthesis of some of the cyclopropane-based conformationally restricted analogs of GABA have been reported, these were limited to the 1,3-methono analogs and were not prepared stereoselectively and/or prepared as a racemate. 11 We successfully systematically synthesized not only the 2,3-methano analogs, but also the 3,4-methano analogs stereoselectively as optically pure forms from the chiral cyclopropane units, which clearly shows that the units are very useful for preparing various conformationally restricted chiral cyclopropane analogs with stereochemical diversity.
Among the newly synthesized 2,3-methano GABA analogs we identified a GAT inhibitor IIa. The anticonvulsive effect of IIa was investigated to confirm whether or not the compound was effective in vivo through the GABAergic system. Thus, IIa effectively prolonged the latency of clonic convulsions in the mouse model. Although the effect (ED 50 = 189 nM) was somewhat weaker than that of the potent GAT1 inhibitor tiagabine (6, ED 50 = 43.7 nM), tremor, which is a typical side effect of tiagabine, was not observed at all by the treatment with IIa. These results suggest an advantage of GAT3 as a drug target molecule for the GABAergic system due to its intensive expression, particularly in astrocytes to regulate GABA levels in the synaptic cleft. However, these are only preliminary results, and further pharmacologic studies are required, because, for considering the in vivo effect of IIa, its binding to BGT1
and GABA A receptor must be taken into account. It is important to note that only IIa has potent inhibitory effects on GAT3 and BGT1 among the eight stereo-and regioisomeric conformationally restricted analogs, which suggests that our stereochemical diversity-oriented conformational restriction strategy worked effectively in this study without the structural data of the target protein. These results show that subtle changes in stereochemical restriction can affect the pharmacological profiles of compounds and that a systematic study by utilizing the stereochemical diversity-oriented conformational restriction strategy allows for exhaustive investigation of the bioactive conformation of compounds in order to develop the desired ligands that bind to the target protein.
The pharmacological potency within a chemical series is often well correlated with MW, and accordingly, lead compounds should be estimated by considering the potency with respect to MW. 12 Recently, ligand efficacy (LE), which is a way of normalizing potency and MW of a compound to provide a useful comparison between compounds with range of MW and activities, has become a useful parameter for lead assessment. 13 Although the inhibitory effects of IIa on GAT3 and BGT1 are not very strong and it also binds to GABA A receptor, IIa has vital importance as a lead for developing useful GAT3 or BGT1 inhibitors, due to its hydrophilic and low-MW properties, namely from the viewpoint of LE. Table 4 inhibitor, IIa also has an excellent LE of 0.90. These results showed that IIa can be a favorable lead for developing potent GAT3 and/or BGT1 inhibitors.
Conclusion.
We used the chiral cyclopropane units effectively to synthesize a series of conformationally restricted GABA analogs and identified a GAT3/BGT1 inhibitor IIa, which can be an effective lead compound for the optimization due to its favorable LE and hydrophilic properties. Thus, the stereochemical diversity-oriented conformational restriction strategy was effective in this study.
Experimental
Chemical shifts are reported in ppm downfield from Me 4 Si ( 1 H) and MeOH ( 13 C in CH 2 Cl 2 (77 mL) was stirred at room temperature for 1 h and filtered with a glass filter. To the filtrate was added the above reaction mixture, and the resulting mixture was stirred at room temperature for 5 h.
The mixture was partitioned between CHCl 3 and aqueouse HCl (1M), and the organic layer was washed with saturated aqueous NaHCO 3 and brine, dried (Na 2 SO 4 ), and evaporated to give an oil (11.0 g). A mixture of the oil, TrCl (10.3 g, 37 mmol) and pyridine (9.9 mL, 123 mmol) in CH 2 Cl 2 (62 mL) was stirred at room temperature for 12 h. The resulting mixture was partitioned between CHCl 3 and H 2 O, and the organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 2:1 then 1:1) to give 15 ( 16.7, 26.5, 48.7, 60.3, 61.9, 87.4, 127.1, 127.8, 128.8, 133.6, 143.8 ; LRMS (FAB) m/z 564 (M+Na) + ;
[α] 19 D −37.3º (c 1.09, CHCl 3 ).
(1R,2R)-2-(Triphenylmethoxymethyl)-1-(N-methoxy-N-methyl)carbamoylcycropropane (12) and (1S,2R)-2-(Triphenylmethoxymethyl)-1-(N-methoxy-N-methyl)carbamoylcycropropane (13) . A mixture of 15 (12.8 g, 24 mmol) and Mg (11.5 g, 0.47 mol) in MeOH/THF (1:2, 120 mL) was stirred at room temperature for 10 min and then at 0 °C for 1h. The resulting mixture was poured into cooled aqueous HCl (1 M), which was extracted with AcOEt. The organic layer was washed with saturated aqueous NaHCO 3 and brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 19:1 then 12:1) to give 12 (5.1 g, 12.8 mmol, 54%) and 13 (3.4 g, 8 .5 mmol, 36%) as oils was aded. The resulting mixture was extracted with CHCl 3 , and the organic layer was washed with saturated aqueous NaHCO 3 and brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 5:1-1:1) to give an oil (3.0 g). A mixture of the oil, Ph 3 P (9.14 g, 34.8 mmol), and CBr 4 (5.78 g, 17.4 mmol) in DMF (67 mL) was stirred at 0 °C for 40 min.
To the mixture was added NaN 3 (5.66 g, 8.71 mmol), and the resulting mixture was stirred at room temperature for 18 h and then evaporated. The residue was partitioned between AcOEt and H 2 O, and the organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 10:1-1:1) to give 16 ( 
.
(1R,2R)-1-(N-t-Butoxycarbonyl)aminomethyl-2-carboxycyclopropane (18).
A solution of 17 (1.8 g, 4.1 mmol) in aqueous AcOH (80%, 41 mL) was stirred at room temperature for 16 h, and then H 2 O was added. The resulting solution was extracted with AcOEt, and the organic layer was washed with saturated aqueous NaHCO 3 and brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 3:1-1:5) to give an oil (709 mg). A mixture of the oil and Dess-Martin periodinane (1.7 g, 4.0 mmol) in CH 2 Cl 2 (35 mL) was stirred at 0 °C for 1h and then at room temperature for 1 h. After addition of a mixture of saturated aqueous Na 2 S 2 O and saturated aqueous NaHCO 3 (1:1), the resulting mixture was extracted with CHCl 3 , and the organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 3:1-1:1) to give an oil (700 mg). A mixture of the oil, 2-methyl-2-butene (3.0 mL), 6.65; N, 9.24. Found: C, 39.39; H, 6.70; N, 8.96 . (1S,2R)-1-Azidomethyl-2-(triphenylmethoxy)methylcyclopropane (19) . Compound 19 (3.1 g, 8.4 mmol, quant., oil) was prepared from 13 (190 mg, 0.50 mmol) as described for the preparation of 16: 8, 14.4, 15.3, 51.1, 63.4, 86.4, 126.9, 127.8, 128.6, 144. , 6.27; N, 11.37. Found: C, 77.75; H, 6.30; N, 11 .07.
(1S,2R)-1-(N-t-Butoxycarbonyl)aminomethyl-2-(triphenylmethoxy)methylcyclopropane (20).
Compound 20 (515 mg, 1.16 mmol, 84%, a white amorphous solid) was prepared from 19 (512 mg, 1.39 mmol) as described for the preparation of 17: 1 H-NMR ( 15.4, 28.4, 40.2, 63.9, 78.5, 86.9, 127.0, 127.9, 128.3, 143.9, 155.9 ; LRMS (FAB) m/z 466 (M+Na) + ;
[α] 24 D −0.6º (c 0.68, CHCl 3 ). 6, 12.3, 21.5, 28.0, 48.0, 82.6, 150.4, 173.8 . (1S,2R) Cl, 23.39; N, 9.24. Found: C, 39.49; H, 6.55; Cl, 23.48; N, 9.30 .
(3R,4S)-N-t-Butoxycarbonyl-3,4-methano-2-pyrrolidone (21
(1S,2R)-2-(t-Butyldiphenylsilyloxy)methyl-1-(2-hydroxyethyl)cyclopropane (22). To a suspension
of MeOCH 2 PPh 3 Cl chloride (12.3 g, 36 mmol) in THF (81 mL) was added NaN(Si(CH 3 ) 3 ) 2 (1.9 M in THF, 17.1 mL, 33 mmol) at 0 °C, and the mixture was stirred at the same temperature for 30 min. To the resulting solution was added a solution of 10 (5.51 g, 16.3 mmol) in THF (80 mL) at 0 °C, and the resulting mixture was stirred at the same temperature for 3 h. After addition of aqueous saturated NH 4 Cl, the solvent of the mixture was evaporated, and the residue was partitioned between AcOEt and H 2 O. The organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 49:1) to give an oil (5.0 g). To a solution of the oil in THF (56 mL) was added a mixture of aqueous HCl (12 M, 17 mL) and THF (80 mL) at 0 C, and the resulting mixture was stirred at the same temperature for 35 smin. To the mixture was added aqueous saturated NaHCO 3 (100 mL), and the resulting solution was extracted with AcOEt. The organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated to give an oil (4.4 g). A mixture of the oil and NaBH 4 (206 mg, 5.5 mmol) in THF/MeOH (4:1, 136 mL) was stirred at room temperature for 5 h, and then aqueous HCl (1M) was aded. The resulting mixture was extracted with CHCl 3 and the organic layer was washed with saturated aqueous NaHCO 3 and brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 8:1-3:1) to give 22 ( 3, 14.4, 19.1, 20.6, 26.8, 35.9, 63.3, 68.3, 127.6, 129.6, 133.4, 135.6; LRMS (FAB) 
(1S,2R)-trans-1-(2-Benzyloxy)ethyl-2-carboxycyclopropane (24).
A mixture of 23 (528 mg, 2.6 mmol) and Dess-Martin periodinane (1.67 g, 3.9 mmol) in CH 2 Cl 2 (26 mL) was stirred at 0 °C for 45 min.
After addition of a mixture of saturated aqueous Na 2 S 2 O and saturated aqueous NaHCO 3 (1:1) , the resulting mixture was extracted with CHCl 3 , and the organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated to give an oil (583 mg). A mixture of the oil, 2-methyl-2-butene (2.17 mL, 21 mmol), NaClO 2 (926 mg, 10 mmol), and NaH 2 PO 4 ·2H 2 O (805 mg, 5.2 mmol) in t-BuOH/H 2 O (24:1, 25 mL) was stirred at room temperature for 2 h. The resulting mixture was partitioned between AcOEt and aqueous HCl (1 M), and the organic layer was washed with brine, dried (Na 2 SO 4 ), and evaporated. The residue was purified by column chromatography (silica gel; hexane/AcOEt, 4:1) to give 24 (547 mg, 97%) as an oil: 1 H-NMR ( 8, 21.0, 33.2, 69.4, 73.0, 127.6, 127.6, 128.4, 138.3, 180.7; LRMS (EI) 13.5, 17.7, 28.4, 29.1, 32.5, 69.6, 72.9, 79.3, 127.5, 127.6, 128.3, 138.6, 156.4; LRMS (FAB) 8.65; N, 4.81. Found: C, 69.77; H, 8.45; N, 4.65 . (1S,2R)-2-(t-Buthoxycarbonyl) 3, 15.8, 28.2, 29.2, 37.7, 80.9, 157.8, 174.5; LRMS (FAB) , 39.15; H, 6.70; N, 9.13. Found: C, 39.08; H, 6.51; N, 9.10 . 8, 20.1, 27.2, 69.9, 72.8, 127.4, 127.5, 128.3, 138.4, 179 15.0, 26.7, 28.3, 28.6, 70.6, 73.2, 78.9, 127.5, 128.4, 129.8, 138.3, 157. , 6.30; N, 11.32. Found: C, 77.60; H, 6.35; N, 11.21 .
(1R,2R)-2-(t-Butyldiphenylsilyloxy)methyl-1-(2-hydroxyethyl)cyclopropane (27
(1S,2S)-1-(N-t-Butoxycarbonyl)aminomethyl-2-(triphenylmethoxy)methylcyclopropane (ent-17):
[α] 21 D +11.0º (c 1.06, CHCl 3 ).
(1S,2S)-1-Aminomethyl-2-carboxycyclopropane hydrochloride (ent-Ia, HCl salt) : [α] 22 D +68.6º (c 0.97, 1 N HCl aq.); m.p. 141.0−145.0 ºC; Anal. Calcd for C 5 H 10 ClNO 2 : C, 39.62; H, 6.65; Cl, 23.39; N, 9.24. Found: C, 39.34; H, 6.44; Cl, 23.14; N, 9.18 . 241−242 ºC); Anal. Calcd for C 5 H 10 ClNO 2 : C, 39.62; H, 6.65; Cl, 23.39; N, 9.24. Found: C, 39.65; H, 6.56; Cl, 23.29; N, 9. 28. , 38.70; H, 6.75; Cl, 22.84; N, 9.03. Found: C, 38.75; H, 6.61; Cl, 22.94; N, 9.13 . 
